Medarex

Medarex

Medarex (/mɛdərɛks/) is a biopharmaceutical company that specializes in the discovery, development, and potential commercialization of fully human antibody-based therapeutics to treat life-threatening and debilitating diseases, including cancer, inflammation, autoimmune disorders, and infectious diseases.

Etymology

The name "Medarex" is derived from the words "medical" and "apex", signifying the company's commitment to reaching the pinnacle of medical innovation.

History

Medarex was founded in 1987 and is headquartered in Princeton, New Jersey. The company was acquired by Bristol-Myers Squibb in 2009.

Technology

Medarex's core technology, the UltiMAb Human Antibody Development System™, is a unique and proprietary process that enables the rapid generation of highly specific, fully human antibodies that can be used as therapeutic agents.

Products

Medarex has developed a number of products, including Ipilimumab, a fully human monoclonal antibody that was approved by the FDA in 2011 for the treatment of melanoma.

Related Terms

• Biopharmaceutical
• Monoclonal Antibody
• Cancer
• Inflammation
• Autoimmune Disorders
• Infectious Diseases
• Bristol-Myers Squibb
• Ipilimumab

External links

• Medical encyclopedia article on Medarex
• Wikipedia's article - Medarex

This WikiMD article is a stub. You can help make it a full article.

---

Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski